[ivory-search id="184" title="Recordati AJAX Search Form"]

Industrial Operations

Pharmaceutical Manufacturing Plants

Recordati’s production sites are equipped with state-of-the-art installations and their research laboratories are fitted with the latest equipment.

 

All plants operate in full compliance with environmental protection regulations and in compliance with the cGMP (current Good Manufacturing Practices).

Pharmaceutical Chemical Plants

The manufacturing of active ingredients has been a core part of Recordati’s history since it was founded in 1926 with Giovanni Recordati transformed the Pharmacy and adjoined chemical laboratory into the “Laboratorio Farmacologico Reggiano”, resulting in the birth of Recordati as a chemical pharmaceutical industrial company.  Since moving its main operations to Milan, the division has grown internationally alongside the broader pharmaceutical business, exporting 90% of its production of APIs and intermediates, selling directly in over 50 Countries and manufacturing intermediates and active ingredients for the Recordati pharmaceutical brands.

A huge variety of vertically integrated operations allow to obtain top quality products starting from very simple raw materials, by managing extremely complex chemical processes. The capabilities related to the utilisation of substances requiring special risk management measures and the possibility to carry out reactions in extreme conditions, such as high temperatures and pressures, are one of the most important components of the manufacturing expertise. A permanent effort is made to keep production lines and areas at the forefront of technology, with relevant investments aimed to continuously improve QHSE management and to develop production capacity, efficiency and flexibility.

Recordati’s Pharmaceutical Chemical Division is committed to establish and maintain a Quality System which meets the international guidelines, including but not limited to ICH Q7 “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”, Eudralex Volume 4 Good Manufacturing Practice (GMP) Guidelines: Part II – “Basic Requirements for Active Substances used asStarting Materials”, Part III “GMP – related document” and Annex 11 “Computerized systems” and CFR 21 part 11. Recordati is recognised as a leader in the market of several high purity APIs and a reliable provider for compendial reference standards. Recordati’s cooperation with the pharmacopoeia expert committees started more than 20 years ago for the proposal of the compendial monographs for the APIs developed by Recordati and more recently Recordati cooperated in the revision of several compendial monographs to introduce high selective methods for related substances determination.

The R&D Department’s main duty is supporting the Recordati Business Development through the fine-tuning of new products and the manufacturing of APIs both for Recordati and other pharmaceutical companies. To this end, a complete set of manufacturing facilities is available both at lab and pilot plant scale, combined with the use of suitable softwares for the process development and tech transfer from the lab to the production plant.

The R&D Department is composed by a team of highly specialised researchers and technicians (5 PhDs in Chemistry, 5 Master’s Degree in Chemistry, 1 Process Engineer, 4 high school graduates) who master most of organic chemistry reactions and production technologies as well as short path distillation, high pressure hydrogenation, flow chemistry. Thanks to highly efficient discovery programmes issue as above, as well as wise alliances with other pharmaceutical and research institutes, Recordati has always been able to successfully implement new products in its portfolio. Commitment, scientific rigour and availability of technological capability in the R&D Department, allow Recordati to develop new treatments and to count on an always innovative product pipeline. In order to constantly ensure high API quality and robustness of the production, the R&D group is involved in a never ending performance improvement cycle; however, the main research and development activities are mainly focused on generating innovative treatments with special care on rare diseases.

Interested in joining our team?

We foster an entrepreneurial environment where high-performing individuals are empowered to make a difference across our organisation.

In Partenza Recordati.com

Stai per lasciare recordati.com per accedere al sito dedicato alle carriere di Recordati

Leaving Recordati.com

You are now leaving recordati.com to enter Recordati’s dedicated career site

INFORMATION ON PERSONAL DATA PROTECTION PURSUANT TO ARTICLE 13 OF LEGISLATIVE DECREE NO. 196/2003

The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.

 

In any event we assure you that your data will be processed solely for the above purposes and using the above methods.

 

The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.

 

A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).

 

Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.

 

In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.

 

Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.